Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (7763)	3/20/2000 1:26:00 PM
From: Ward Knutson	Respond to of 9719

<<Yes, bright expectations might make you more willing to expand your current salesforce, but not unless something else drives the timing.>> Correct. The Company has stated the expansion is to serve two fronts; anticipation of eventual Irofulven launch (there is a lot of prepratory work needed for such), and the business development efforts presently underway (new products, through either acquisition or cross-licensing or perhaps a combination of the two). Blitzer is assembling a very strong management & sales team, with a proven track record in my opinion. I believe they are on the trail of building a very special and much larger niche pharma - they will utilize the power of holding an asset like the acylfulvene family to accelerate their efforts. Ward